Skip to main content
IRS-authorized e-file provider · not the IRS

Nonprofit · EIN 47-2589708

AMYLOIDOSIS RESEARCH CONSORTIUM INC

Tax-exempt · NEWTON, MA 02460

Financials

$2.9M$2.4M2023$3.4M$3M2024$3.8M$3.8M2025
Revenue Expenses · by fiscal year end
Financials of AMYLOIDOSIS RESEARCH CONSORTIUM INC by year, from its e-filed returns
Year endedFormRevenueExpensesNet incomeTotal assetsLiabilitiesNet assets
December 31, 2025990$3,777,620$3,808,975-$31,355$5,365,184$2,255,562$3,109,622
December 31, 2024990$3,366,811$3,016,006$350,805$4,674,963$1,590,167$3,084,796
December 31, 2023990$2,888,025$2,415,059$472,966$2,975,266$226,503$2,748,763
Financial details: 990 for the year ended December 31, 2025

Revenue

Contributions, gifts and grants
$3,548,365
Program service revenue
$50,340
Investment income
$177,115
Other revenue
$1,800

Expenses

Grants and similar amounts paid
$532,500
Other salaries and wages
$2,006,078
Salaries, compensation and benefits (total)
$2,343,758
Professional fundraising fees
$0
Legal fees
$10,744
Accounting fees
$80,047
Occupancy
$13,675
Travel
$68,140
Depreciation
$3,068
Program services (functional)
$2,862,578
Management and general (functional)
$381,132
Fundraising (functional)
$565,265

Balance sheet and other

Total assets, start of year
$4,674,963
Total assets, end of year
$5,365,184
Total liabilities, end of year
$2,255,562
Net assets, end of year
$3,109,622
Land, buildings and equipment
$99
Publicly traded securities
$4,649,029
Net assets without donor restrictions
$2,328,345
Net assets with donor restrictions
$781,277
Gross receipts
$3,777,620
Employees
19
Volunteers
0
Year formed
2015
State of legal domicile
MA

From the e-filed returns the IRS publishes as XML (latest three processing years; amended returns replace the original). PDF copies at the IRS.

Officers, directors and key employees

As listed on the 990 for the year ended December 31, 2025, highest compensation first.

NameTitleHours / weekCompensation
ISABELLE LOUSADAPRESIDENT/CEO & CLERK
Trustee or director, Officer
40$199,327
SARAH CAIRNS-SMITHCHAIR
Trustee or director, Officer
0.25$0
DENA HEATHBOARD MEMBER
Trustee or director
0.25$0
DR RAYMOND COMENZOBOARD MEMBER
Trustee or director
0.25$0
JASON SHORETREASURER
Trustee or director, Officer
0.25$0
ASHUTOSH WECHALEKARBOARD MEMBER
Trustee or director
0.25$0
LAURA STRICKLANDBOARD MEMBER
Trustee or director
0.25$0
MARK GUIDINGERBOARD MEMBER
Trustee or director
0.25$0
KENA THOMPSONBOARD MEMBER
Trustee or director
0.25$0
990 for the year ended December 31, 2024: 8 people
NameTitleHours / weekCompensation
ISABELLE LOUSADAPRESIDENT/CEO & CLERK
Trustee or director, Officer
40$175,000
SARAH CAIRNS-SMITHCHAIR
Trustee or director, Officer
0.25$0
RICK NATHANSONBOARD MEMBER
Trustee or director
0.25$0
DR RAYMOND COMENZOBOARD MEMBER
Trustee or director
0.25$0
JASON SHORETREASURER
Trustee or director, Officer
0.25$0
ASHUTOSH WECHALEKARBOARD MEMBER
Trustee or director
0.25$0
LAURA STRICKLANDBOARD MEMBER
Trustee or director
0.25$0
MARK GUIDINGERBOARD MEMBER
Trustee or director
0.25$0
990 for the year ended December 31, 2023: 7 people
NameTitleHours / weekCompensation
ISABELLE LOUSADAPRESIDENT/CEO & SECRETARY
Trustee or director, Officer
40$178,365
SARAH CAIRNS-SMITHCHAIR
Trustee or director, Officer
0.25$0
RICK NATHANSONBOARD MEMBER
Trustee or director
0.25$0
DR RAYMOND COMENZOBOARD MEMBER
Trustee or director
0.25$0
JASON SHORETREASURER
Trustee or director, Officer
0.25$0
DENA HEATHBOARD MEMBER
Trustee or director
3$0
DR ASHUTOSH WECHALEKARBOARD MEMBER
Trustee or director
0.25$0

Address and contacts

Address (IRS master file)
320 NEVADA ST STE 210, NEWTON, MA 02460-1435
Principal officer (990 for 2025)
ISABELLE LOUSADA, 320 NEVADA STREET SUITE 210, NEWTON, MA 02460
Signed the 990
ISABELLE LOUSADA, CEO & CLERK
Phone
(617) 899-8810
Return prepared by
JAMES A GEORGE PC

Mission

ACCELERATING THE DEVELOPMENT OF ADVANCED DIAGNOSTIC TOOLS AND EFFECTIVE TREATMENTS FOR SYSTEMIC AMYLOIDOSIS THROUGH COLLABORATION AND INNOVATION.

990 for the year ended December 31, 2025

Program accomplishments

  • RESEARCH PROGRAMS:ARC HAS BEEN WORKING ON A NUMBER OF RESEARCH INITIATIVES INCLUDING DATASHARING, AND PATIENT EXPERIENCE STUDIES. ARC HAS ALSO DEVELOPED AN APPOINTMENT COMPANION TOOL THAT SUPPORTS PATIENTS THROUGHOUT THEIR TREATMENT JOURNEY. THE ANONYMIZED AGGREGATED DATA PROVIDES VALUABLE REAL WORLD INCITES. ARC IS DEVELOPING A PATIENT REPORTED OUTCOMES TOOL FOR USE IN CLINICAL PRACTICE.
    Expenses $589,943 · revenue $52,140
  • AWARENESS, EDUCATIONAL PROGRAMS AND ADVOCACY:ARC'S PATIENT AND HEALTHCARE PROFESSIONAL PROGRAMS EDUCATE PHYSICIANS AND TAILOR INFORMATION TO SUIT THE PATIENT'S NEEDS AND ARE SUCCESSFULLY MATCHING THEM TO BETTER TREATMENT CENTERS, CARE, AND CLINICAL TRIALS. ARC'S PATIENT ADVISORY BOARD ARE INSTRUMENTAL IN DEFINING AND PRIORITIZING ARC'S PATIENT PROGRAMS. ARC'S PATIENT SUPPORT SPECIALIST PROVIDES INFORMATION AND GUIDANCE FOR PATIENTS THROUGHOUT THEIR JOURNEY. ARC ALSO MAINTAINS A COMPREHENSIVE WEBSITE WITH THE LATEST INFORMATION AND NEWS ABOUT AMYLOIDOSIS. ARC'S UNIQUE AMYLOIDOSIS PATHFINDER TOOL SUPPORTS PATIENTS IN FINDING AND EVALUATING TREATMENT CENTERS AND MATCHING THEM WITH CLINICAL TRIALS. THIS TOOL HAS BEEN FURTHER ENHANCED TO SUPPORT PATIENTS WITH TELEHEALTH VISITS AND VIRTUAL CARE DURING THE PANDEMIC. ARC ALSO HOSTS ARC TALKS, A REGULAR PATIENT EDUCATIONAL WEBINAR SERIES COVERING A RANGE OF IMPORTANT TOPICS. ARC HAS DEVELOPED BOOKLETS, AND HANDOUTS TO PROVIDE PATIENTS WITH IN DEPTH INFORMATION ON AMYLOIDOSIS RELATED TOPICS.
    Expenses $714,179
  • HEALTHCARE PROFESSIONAL EDUCATION:ARC HAS CARRIED OUT RESEARCH TO UNDERSTAND THE BARRIERS AND PATHWAYS TO EARLY DIAGNOSIS. FROM THIS RESEARCH, ARC DEVELOPED AND IMPLEMENT TARGETED SOLUTIONS. ARC RAISES AWARENESS AND PROVIDES PHYSICIAN EDUCATION ON THE SIGNS, SYMPTOMS, AND CARE OF AMYLOIDOSIS TO RAISE THE LEVEL OF SUSPICION, IMPROVE THE SPEED OF DIAGNOSIS, AND STANDARDS OF CARE. ARC HELD A MASTERCLASS FOR PHYSICIANS AND NURSES IN DALLAS, TX FOCUSED ON ADDRESSING THE CHALLENGES OF ACCURATE DIAGNOSIS AND MANAGING CARE. ARC HAS PUBLISHED PEER REVIEWED CONSENSUS GUIDELINES DEFINING PATHWAY FOR SUSPICION AND DIAGNOSIS WITH A FOCUS ON CARDIOLOGY AND GENERAL PRACTICE. ARC SPONSORED A SATELLITE SYMPOSIUM AT THE HFSA CONFERENCE ON THE DIAGNOSIS AND TREATMENT OF CARDIAC AMYLOIDOSIS.
    Expenses $570,861
  • Expenses $987,595 · grants $532,500

What it must file and when

IRS records say it files Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N. Its accounting year ends in December, so each return is due on the 15th day of the 5th month after that.

Tax yearYear endedDueIRS public records
2025December 31, 2025May 15, 2026990 on file
2024December 31, 2024May 15, 2025990 on file
2023December 31, 2023May 15, 2024990 on file

IRS record

EIN
47-2589708
Tax-exempt status
501(c)(3): Charitable, religious, educational or scientific organization
Foundation status
Publicly supported organization (170(b)(1)(A)(vi))
Donations deductible (Pub 78)
Public charity, 50% deduction limit
Exempt since
2015
Accounting year ends
December
Files
Form 990 or 990-EZ
Category (NTEE)
Medical research (H80)
Assets (IRS master file)
$5,365,184
Income (IRS master file)
$3,777,620

Filing history

FormYear endedRevenueExpensesAssetsReturn
990December 2025$3,777,620$3,808,975$5,365,184XML
990December 2024$3,366,811$3,016,006$4,674,963IRS
990December 2023$2,888,025$2,415,059$2,975,266XML
990December 2022$2,260,256$2,129,932$2,516,230IRS
990December 2021–––IRS
990December 2020–––IRS
990December 2018–––IRS

990-N: the IRS bulk file holds only the latest e-Postcard per organization; earlier years come from archived copies of that file since 2020 and can have gaps (the IRS e-Postcard search lists every one). 990, 990-EZ, 990-PF, 990-T: every e-filed return in the IRS e-file index since 2019; XML for the latest three processing years, amounts from the IRS Statistics of Income extracts before that. PDF copies and determination letters at the IRS (search EIN 47-2589708).

Questions about AMYLOIDOSIS RESEARCH CONSORTIUM INC

What is the EIN of AMYLOIDOSIS RESEARCH CONSORTIUM INC?
The employer identification number (EIN) of AMYLOIDOSIS RESEARCH CONSORTIUM INC is 47-2589708.
Is AMYLOIDOSIS RESEARCH CONSORTIUM INC tax-exempt?
Yes. The IRS lists it as tax-exempt under section 501(c)(3) since 2015.
Are donations to AMYLOIDOSIS RESEARCH CONSORTIUM INC tax-deductible?
Yes. It is listed in IRS Publication 78 (Public charity, 50% deduction limit).
Which annual return does AMYLOIDOSIS RESEARCH CONSORTIUM INC file?
Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N.
When is the next return of AMYLOIDOSIS RESEARCH CONSORTIUM INC due?
The return for tax year 2026 (the year ending December 31, 2026) is due May 17, 2027. Form 8868 extends it by six months; the 990-N cannot be extended.
When did AMYLOIDOSIS RESEARCH CONSORTIUM INC last file with the IRS?
The latest return in the IRS public files is the 990 for the year ended December 2025.
Who is the principal officer of AMYLOIDOSIS RESEARCH CONSORTIUM INC?
The 990 for the year ended December 31, 2025 names ISABELLE LOUSADA.
Who are the officers and directors of AMYLOIDOSIS RESEARCH CONSORTIUM INC?
The 990 for the year ended December 31, 2025 lists 9 people; 1 received compensation from the organization, the highest $199,327 (ISABELLE LOUSADA, PRESIDENT/CEO & CLERK).
How much revenue does AMYLOIDOSIS RESEARCH CONSORTIUM INC have?
On its 990 for the year ended December 31, 2025 it reported revenue of $3,777,620, expenses of $3,808,975 and total assets of $5,365,184 at year end.

Other nonprofits in NEWTON

All nonprofits in NEWTON · Massachusetts · Medical research